BUZZ-India's Dr Reddy's rises after EU marketing authorisation for osteoporosis biosimilar

Reuters11-25
BUZZ-India's Dr Reddy's rises after EU marketing authorisation for osteoporosis biosimilar

** Shares of Dr Reddy's REDY.NS rise 1.4% to 1,243.30 rupees

** Set to snap three sessions of losses

** European Commission grants pharma co marketing authorisation for AVT03, a biosimilar to Prolia and Xgeva

** These medicines are used to treat osteoporosis and prevent cancer related bone issues

** Last May, REDY and Alvotech ALVO.O entered into a license and supply agreement to commercialize the biosimilar

** REDY has exclusive commercialization rights in the U.S. and semi-exclusive rights in Europe and UK

** Biosimilars are copies of costlier biological drugs used to treat major illnesses

** Thirty eight analysts have a "hold" rating on avg; median PT is 1,305 rupees - data compiled by LSEG

** YTD, REDY down 10.5%

(Reporting by Urvi Dugar in Bengaluru)

((UrviManoj.Dugar@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment